Prognostic role of targeting protein for Xklp2 in solid tumors
A PRISMA-compliant systematic review and meta-analysis
Shijie Wang, MD, Yongyuan Chen, MD, Ying Chai, MD*

Abstract
Background: The prognostic role of targeting protein for Xklp2 (TPX2) in solid tumors has been investigated in several researches, but the results remain controversial. Here we present a meta-analysis to systematically review the association between TPX2 expression levels and prognosis of human solid tumors.

Methods: Studies published until December 2017 were searched in PubMed, Web of Science, and EBSCO. 13 studies (2134 patients) were collected for analysis. Odds ratios (ORs) for overall survival (OS) and disease-free survival (DFS) from individual studies were calculated by the application of Mantel-Haenszel random effect model. Pooled ORs were estimated by Z test. Publication bias and interstudy heterogeneity analyses were also performed.

Results: TPX2 overexpression was associated with poor OS at 3 and 5 years [OR=4.63, 95% confidence interval (CI): 3.27–6.56, P<.00001; OR=4.05, 95% CI: 2.32–7.07, P<.00001, respectively] of solid tumors. Similar results were observed with DFS at 3 and 5 years (OR=3.35, 95% CI: 1.83–6.14, P<.0001; OR=2.94, 95% CI: 1.74–4.98, P<.0001, respectively). Subgroup analysis revealed that increased TPX2 expression was related to worse prognosis of gastric cancer and hepatocellular cancer, while irrelevant to esophageal squamous cell cancer at 5-year survival rate.

Conclusions: Overexpression of TPX2 is related to poor survival rate in most solid tumors, which indicates that the expression level of TPX2 is a significant prognostic and potential therapeutic target in various solid tumors.

Abbreviations: CI = confidence interval, DFS = disease-free survival, IHC = immunohistochemistry, MAP = microtubule-associated protein, MT = microtubule, NOS = Newcastle-Ottawa Scale, OR = odds ratio, OS = overall survival, PLK1 = polo-like kinase 1, TPX2 = targeting protein for Xklp2.

Keywords: disease-free survival, meta-analysis, overall survival, prognosis, solid tumors, targeting protein for Xklp2.

1. Introduction
Targeting protein for Xklp2 (TPX2) is a proliferation-related protein first described by Heidebrecht et al. who found a nuclear antigen roughly 100kDa molecular mass exclusively expressed in S, M, and G2 phases, and named p100 at that time. Before long, Vernos’ group discovered that this novel cell cycle-related protein played an essential role in the localization of GST-Xklp2-tail to microtubule (MT) minus ends. Further studies indicated that TPX2 controlled MT nucleation, function, and interaction with other cell structures as an MT-associated protein (MAP), and improper expression of TPX2 lead to chromosomal instability, caused centrosome amplification, and developed aneuploidy, which highly correlated with the occurrences and developments of various tumors. More recently, researchers found TPX2 promoted the proliferation and migration of tumor cells by regulating Aurora-polo-like kinase 1 (PLK1) cascades, which worked as key signaling modules in mitosis. As a result, TPX2/Aurora-PLK1 signaling might be a potential therapeutic target in malignant tumors. Huang et al. reported TPX2 silencing mediated by the joint action of microvesicles and ultrasonic radiation significantly inhibited the progression of SKOV3 cells, indicating an effective gene therapy against ovarian cancer.

Several research groups have paid special attention to the relationship between TPX2 expression and various human tumors, strong research evidence revealed that in most human cancers, such as lung, hepatic, colon, pancreatic, salivary gland, breast, and cervical cancers, TPX2 proved to be highly expressed. However, the prognostic value of the TPX2 expression in various solid tumors is still controversial. Independent studies showed that in most cases overexpression of TPX2 had a negative impact on the prognosis of various types of solid tumors, such as astrocytoma, ovarian cancer, renal cell cancer, gastric cancer, bladder cancer, esophageal squamous cell cancer, hepatocellular cancer, and lung cancer. However, Pan et al. found that the expression of TPX2 in tumor tissues of patients with prostate cancer was not related to their survival time. Therefore, to clarify a better understanding of the prognostic significance of TPX2 overexpression in human solid tumors, we...
performed a meta-analysis combining 13 studies (2134 patients) as well as subgroups analysis, aiming to assess the correlation of elevated TPX2 expression with survival in solid tumors, and to learn a bit more about the clinical role of TPX2 as a therapeutic target and prognostic biomarker for solid tumors.

2. Methods

This meta-analysis was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.[31] This study is a summary and analysis of previous published studies, so there is no need for ethical approval.

2.1. Identification and selection of studies

We searched 3 different online databases, EBSCO, PubMed, and Web of Science, for studies that evaluated the relationship between TPX2 expression and survival in solid tumors until December 2017. The search terms included “Targeting protein for Xklp2” or “TPX2” or “DIL-2” or “C20orf2” and “neoplasms,” the search results were limited to the studies of human solid tumors. No publication time and language restrictions were imposed. Of the 3 databases, we identified 97, 85, and 204 items, respectively. The inclusion criteria were the literatures provided overall survival (OS) data or disease-free survival (DFS) data or both of them, follow-up time at least 3 years and writing in English. We manually filtered the retrieved articles to guarantee the sensitivity of the search strategy. Interrater reliability was evaluated by Cohen kappa coefficient. If there were disagreements, resolved through consensus.

2.2. Endpoints of interest

The primary endpoints were 3- or 5-year OS or DFS. Patients were assigned to control or experimental arms according to the TPX2 expression cut-off values defined by individual studies.

2.3. Data extraction

Two authors (SW and YC) independently reviewed the articles and extracted information using predesigned data form, which contained the publication time and first author of article, country of origin, tumor type, number of patients, age, histological type and stage, follow-up time, cut-off to determine TPX2 positivity, number of TPX2 positive patients and controls, detection method, and outcome endpoint. Survival data were extracted

---

Figure 1. Flow diagram of the meta-analysis process. DFS = disease-free survival, OS = overall survival.
Table 1
Characteristics of studies included in the meta-analysis.

| Ref | Type of cancer | City, country | No. | Age, y | Male/Female | Stage | Follow-up, mo | Detection method | 3-Year OS or DFS (%) | 5-Year OS or DFS (%) | NOS |
|-----|----------------|---------------|-----|-------|-------------|-------|--------------|------------------|---------------------|---------------------|-----|
| Bin Li et al (2010) | Malignant astrocytoma | Shanghai, China | 52 | NR | NR | I, II, III, and IV | NR | Immunohistochemistry | 13/39 | 22.9/40.6 | NA | 6 |
| Bo Liang et al (2016) | Gastric cancer | Nanchang, China | 115 | <55 | 56 | 78 | I, II, III, and IV | NR | Immunohistochemistry | 54/61 | 27.6/70.3 | NA | 8 |
| Cuijie Shao et al (2016) | Gastric carcinoma | Binzhou, China | 106 | 53 | (Range 28–75) | 67/39 | I, II, III, and IV | 101 | (Range 1–118) | Immunohistochemistry | 71/35 | 13.2/74.4 | 7.4/49 | 8 |
| Hung-Wei Pan et al (2017) | Prostate cancer | NR | 467 | | | | | | RNA-sequencing | 276/191 | 97.3/98.4 | 95.8/92.7 | 5 |
| Katia Y et al (2014) | Epithelial ovarian cancer | Montreal, Canada | 131 | 62.6 | ±13.8 | 62.6 | (Range 34–87) | NR | I, II, III, and IV | NR | Immunohistochemistry | 86/19 | 34.7/70.4 | 17.8/43.6 | 8 |
| Liang Yan et al (2013) | Bladder cancer | Henan, China | 71 | <60 | 60 | 46 | T1, T2, T3, T4 | 60 | Immunohistochemistry | 71/35 | 13.2/74.4 | 7.4/49 | 8 |
| Ping Wei et al (2013) | Colon cancer | Shanghai, China | 203 | 65 | ±122 | 65 | Immunohistochemistry | 124 | 78.9/93.7 | 56.4/80.6 | 8 |
| PO-Kuei Hsu et al (2014) | Esophageal squamous cell carcinoma | Taiwan, China | 16 | 62.6 | ±13.8 | 62.6 | Immunohistochemistry | 7/7 | 14.3/42.9 | 14.3/28.6 | 8 |
| Po-Kuei Hsu et al (2014) | Esophageal squamous cell carcinoma | Taiwan, China | 97 | 61.0 | ±12.5 | 61.0 | Immunohistochemistry | 40/56 | 20/38.2 | 12.4/28.8 | 8 |
| Qi Chen et al (2016) | Renal cell carcinoma | Xi'an, China | 286 | Male: 61.1 | ±16.3 | Female: 62.5 | ±17.4 | 192/34 | I, II, III, and IV | 72 | Immunohistochemistry | 179/56 | 38.8/70.5 | 26.8/65.7 | 8 |
| Qingquan Liu et al (2015) | Hepatocellular carcinoma | Xi'an, China | 130 | 52 | (Range 33–76) | 104/26 | I, II, III, and IV | 55 | (Range, 3–79) | Immunohistochemistry | 62/68 | 45.8/86.6 | 31.5/69.6 | 9 |
| Ying Ma et al (2006) | Lung cancer | Beijing, China | 82 | <50 | 27 | 69/17 | I, II, III, and IV | NR | Immunohistochemistry | 48/34 | 24.6/70.5 | 16.7/58.8 | 6 |
| Yuqi Huang et al (2014) | Hepatocellular carcinoma | Guangzhou, China | 86 | 61.0 | ±12.5 | 61.0 | Immunohistochemistry | 56/50 | 31.6/56.1 | 19.1/46.2 | 7 |
| Dingliang Yang et al (2017) | Gastric cancer | Tokyo, Japan | 200 | <65 | 129 | 219/71 | T1, T2, T3, T4 | 62 | (Range, 2–111) | Immunohistochemistry | 123/167 | 72/84.9 | 69.9/62.8 | 8 |
| Po-Kuei Hsu et al (2014) | Esophageal squamous cell carcinoma | Taiwan, China | 16 | 62.6 | ±13.8 | 62.6 | Immunohistochemistry | 7/7 | 14.3/42.9 | 14.3/28.6 | 8 |
| Po-Kuei Hsu et al (2014) | Esophageal squamous cell carcinoma | Taiwan, China | 97 | 61.0 | ±12.5 | 61.0 | Immunohistochemistry | 40/56 | 20/38.2 | 12.4/28.8 | 8 |
| Qingquan Liu et al (2015) | Hepatocellular carcinoma | Xi'an, China | 130 | 52 | (Range, 33–76) | 104/26 | I, II, III, and IV | 55 | (Range, 3–79) | Immunohistochemistry | 62/68 | 45.8/86.6 | 31.5/69.6 | 9 |
| Yuqi Huang et al (2014) | Hepatocellular carcinoma | Guangzhou, China | 86 | <50 | 27 | 69/17 | I, II, III, and IV | NR | Immunohistochemistry | 56/50 | 27.3/75 | 16.1/55.5 | 9 |

DFS = disease-free survival, IHC = immunohistochemistry, NOS = Newcastle-Ottawa Scale, NR = not reported, OS = overall survival.
### Table 2

**Evaluation of human targeting protein for Xklp2 by different detection method in the selected studies.**

| Ref                          | Type of cancer          | Detection method | TPX2+ Tumor (%) | Cutoff for overexpression |
|------------------------------|-------------------------|------------------|----------------|--------------------------|
| Bin Li et al (2010)          | Malignant astrocytoma   | Immunohistochemistry | 25.00          | Immunoreactivity was classified according to the staining intensity and staining-positive cells proportion, and the overexpression of TPX2 was defined as strongly positive immunoreactivity (experimental group) |
| Bo Liang et al (2016)        | Gastric cancer          | Immunohistochemistry | 46.96          | Immunoreactivity was classified according to the overall staining index (OSI) by multiplying the scores of staining intensity (0 = no staining; 1 = weak staining; 2 = moderate staining; or 3 = strong staining) and staining-positive cells proportion (0, no staining; 1, <10% staining; 2, 10%–40% staining; or 3, >40% staining). The overexpression of TPX2 was defined as OSI > 1 (experimental group) |
| Chiharu Tomii et al (2017)   | Gastric cancer          | Immunohistochemistry | 42.41          | <5% Stained cells (control group) vs ≥5% stained cells (experimental group) |
| Bo Liang et al (2016)        | Gastric carcinoma       | Immunohistochemistry | 66.98          | Immunoreactivity was classified according to the overall staining index (OSI) by multiplying the scores of staining intensity (0 = no staining; 1 = weak staining; 2 = moderate staining; or 3 = strong staining) and staining-positive cells proportion (0, no staining; 1, 0–10% staining; 2, 11–30% staining; 3, 31–70% staining; or 4, >71% staining). The overexpression of TPX2 was defined as OSI more than 0 (experimental group) |
| Hung-Wei Pan et al (2017)    | Prostate cancer         | RNA-sequencing    | 59.10          | Overexpression of TPX2 was defined according to the cutoff value (6.8805) based on the 95th percentage expression level of 52 normal solid tissues |
| Katia Y et al (2014)         | Epithelial ovarian cancer | Immunohistochemistry | 81.90          | Immunoreactivity was classified according to the staining intensity (0 = no staining; 1 = weak staining; 2 = moderate staining; or 3 = strong staining). The overexpression of TPX2 was defined as scores more than 0 (experimental group) |
| Cuijie Shao et al (2016)     | Gastric carcinoma       | Immunohistochemistry | 61.08          | Immunoreactivity was classified according to the overall staining index (OSI) by adding up the scores of staining intensity (0 = no staining; 1 = weak staining; 2 = moderate staining; or 3 = strong staining) and staining-positive cells proportion (0, no staining; 1, 1%–10% staining; 2, 11%–30% staining; 3, 31%–50% staining; 4, >50% staining). The overexpression of TPX2 was defined as OSI more than 2 (experimental group) |
| Po-Kuei Hsu et al (2014), dDNA microarray cohort | Esophageal squamous cell carcinoma | dDNA microarray | 50.00          | Overexpression of TPX2 was defined according to the median expression level of 16 patients |
| Po-Kuei Hsu et al (2014), IHC cohort | Esophageal squamous cell carcinoma | Immunohistochemistry | 41.67          | Immunoreactivity was classified according to the overall staining index (OSI) by multiplying the scores of staining intensity (0 = no staining; 1 = weak staining; 2 = moderate staining; or 3 = strong staining) and staining-positive cells proportion (0, no staining; 1, 1%–25% staining; 2, 26%–75% staining; 3, >75% staining). The overexpression of TPX2 was defined as OSI > 0 (experimental group) |
| Qi Chen et al (2016)         | Renal cell carcinoma    | Immunohistochemistry | 76.17          | Immunoreactivity was classified according to the overall staining index (OSI) by multiplying the scores of staining intensity (0 = no staining; 1 = weak staining; 2 = moderate staining; or 3 = strong staining). The overexpression of TPX2 was defined as OSI more than median score (experimental group) |
| Qingquan Liu et al (2019)    | Hepatocellular carcinoma | Immunohistochemistry | 47.69          | Immunoreactivity was classified according to the overall staining index (OSI) by multiplying the scores of staining intensity (0 = no staining; 1 = weak staining; 2 = moderate staining; or 3 = strong staining) and staining-positive cells proportion (0, no staining; 1, 1%–10% staining; 2, 11%–50% staining; 3, 51%–80% staining; 4, >80% staining). The overexpression of TPX2 was defined as OSI more than median score (experimental group) |
| Ying Ma et al (2006)         | Lung cancer             | Immunohistochemistry | 58.54          | Immunoreactivity was classified according to the staining-positive cells proportion (0, no staining; 1, 1%–10% staining; 2, 11%–30% staining; 3, 31%–50% staining; 4, >50% staining). The overexpression of TPX2 was defined as scores >1 (experimental group) |
| Youqi Huang et al (2014)     | Hepatocellular carcinoma | Immunohistochemistry | 65.12          | Immunoreactivity was classified according to the staining-positive cells proportion (0, no staining; 1, 1%–10% staining; 2, 11%–30% staining; 3, 31%–50% staining; 4, >50% staining). The overexpression of TPX2 was defined as scores >0 (experimental group) |

IHC = immunohistochemistry, OSI = overall survival, TPX2+ = targeting protein for Xklp2.
3. Results

3.1. Search results and study characteristics

A total of 386 records were retrieved from 3 databases by the initial search. After carefully reviewing, 13 studies with 2134 patients were finally included in our meta-analysis (Fig. 1). Characteristics of studies with OS or DFS data are presented in Table 1. Of these studies, 3 evaluated gastric cancer,[22–24] 2 evaluated hepatocellular cancer,[22,27] and 1 each evaluated malignant astrocytoma,[19] prostate cancer,[30] epithelial ovarian cancer,[20] bladder carcinoma,[25] colon cancer,[26] esophageal squamous cell cancer,[26] renal cell cancer,[21], and squamous cell lung carcinoma.[29] The quality scores of included studies varied from 5 to 9. Ten of 13 studies scored >6 points and considered to be high-quality researches (see Table, Supplemental Content, http://links.lww.com/MD/C585, which illustrates the quality scores of enrolled studies by Newcastle-Ottawa Quality Assessment).

3.2. Evaluation and expression of TPX2

Table 2 presents the TPX2 detection methods and cut-off values for TPX2 overexpression defined in the individual studies. Eleven investigations detected the TPX2 status by immunohistochemistry (IHC), 1 study used RNA-Sequencing, and the remaining 1 research used 2 detection methods, IHC, and cDNA microarray, respectively. For the IHC method, the cut-off points for TPX2 were 2-tailed, and statistical significance was defined as \( P \leq .05.\)
### Figure 3.

Forest plots showing odds ratios of TPX2- versus TPX2+ of all patients with solid tumors for DFS at 3 and 5 years. A. 3-year DFS; B. 5-year DFS. CI = confidence interval, DFS = disease-free survival, TPX2 = targeting protein for Xklp2.

| Study or Subgroup | TPX2- Events | TPX2- Total | Weight | Odds Ratio M-H, Random, 95% CI |
|-------------------|--------------|-------------|--------|-------------------------------|
| **A. 3-year DFS** |
| Chiharu Tomii, et al. (2017) | 142 | 167 | 89 | 123 | 18.0% | 2.17 [1.21, 3.88] |
| Po-Kuei Hsu, et al. (2014)-HCo | 3 | 7 | 1 | 7 | 1.9% | 4.50 [0.34, 60.15] |
| Po-Kuei Hsu, et al. (2014)-CDNA microarray cohort | 19 | 56 | 5 | 40 | 8.6% | 3.59 [1.21, 10.67] |
| Qiongquan Liu, et al. (2015) | 51 | 68 | 17 | 62 | 13.3% | 7.94 [3.63, 17.37] |
| Yujie Huang, et al. (2014) | 12 | 30 | 14 | 56 | 10.4% | 2.00 [0.77, 5.16] |
| **Subtotal (95% CI)** | 128 | 288 | | | | 3.35 [1.83, 6.14] |
| **Total events** | 227 | 126 | | | | |
| Heterogeneity: Tau² = 0.22; Chi² = 7.96, df = 4 (P = 0.09); I² = 50% |
| Test for overall effect: Z = 3.92 (P < 0.0001) |

| **B. 5-year DFS** |
|-------------------|--------------|-------------|--------|-------------------------------|
| Chiharu Tomii, et al. (2017) | 138 | 167 | 86 | 123 | 18.7% | 2.05 [1.17, 3.57] |
| Po-Kuei Hsu, et al. (2014)-HCo | 2 | 7 | 1 | 7 | 1.8% | 2.40 [0.16, 34.93] |
| Po-Kuei Hsu, et al. (2014)-CDNA microarray cohort | 16 | 56 | 5 | 40 | 8.4% | 2.80 [0.93, 8.43] |
| Qiongquan Liu, et al. (2015) | 38 | 68 | 10 | 62 | 12.4% | 6.59 [2.48, 15.09] |
| Yujie Huang, et al. (2014) | 5 | 30 | 5 | 56 | 6.3% | 2.04 [0.54, 7.70] |
| **Subtotal (95% CI)** | 328 | 288 | 47.7% | 2.94 [1.74, 4.98] |
| **Total events** | 199 | 107 | | | | |
| Heterogeneity: Tau² = 0.10; Chi² = 5.55, df = 4 (P = 0.24); I² = 28% |
| Test for overall effect: Z = 4.01 (P < 0.0001) |

### Figure 4.

Subgroup analysis of overall survival (OS) at 3 and 5 years by the expression level of TPX2 in different cancer types. A. Gastric cancer and 3-year OS; B. Esophageal squamous cell cancer and 3-year OS; C. Hepatocellular cancer and 3-year OS; D. Esophageal squamous cell cancer and 5-year OS; E. Hepatocellular cancer and 5-year OS. CI = confidence interval, TPX2 = targeting protein for Xklp2.
positive or high expression according to the combination of masculine cells proportion and the staining intensity.

### 3.3. Association of TPX2 with survival

There were a total of 12 studies provided the OS data at 3 years, and 10 studies at 5 years. Results showed that TPX2 expression increased in tumor tissue had a negative effect to 3-year OS ($\text{OR} = 4.63, 95\% \text{ CI: } 3.27–6.56, P < .00001$), and 5-year OS ($\text{OR} = 4.09, 95\% \text{ CI: } 1.06–15.80, P = .04$) (Fig. 2). Similarly, 4 studies reported survival data for both 3 and 5-year DFS, results showed that elevated TPX2 expression was also related with obviously poor 3-year DFS ($\text{OR} = 3.35, 95\% \text{ CI: } 1.83–6.14, P < .0001$), and 5-year DFS ($\text{OR} = 2.94, 95\% \text{ CI: } 1.74–4.98, P < .0001$) of solid cancers (Fig. 3). There was low or moderate heterogeneity of the data among studies. Thus, we performed subgroup meta-analysis to figure out whether the various cancer types lead to the heterogeneity.

In the following analysis of subgroups classified by different cancer types, we discovered that TPX2 expression was related to the worse 3-year OS of gastric cancer ($n = 2$, $\text{OR} = 10.63, 95\% \text{ CI: } 3.41–33.15, P < .0001$) (Fig. 4A), esophageal squamous cell cancer ($n = 2$, $\text{OR} = 2.58, 95\% \text{ CI: } 1.06–6.28, P = .04$) (Fig. 4B), and hepatocellular cancer ($n = 2$, $\text{OR} = 4.74, 95\% \text{ CI} = 1.68–13.39, P = .003$) (Fig. 4C). Consistent with the results above, TPX2 expression was related to the worse 5-year OS of hepatocellular cancer ($n = 2$, $\text{OR} = 4.25, 95\% \text{ CI: } 2.36–7.67, P < .00001$) (Fig. 4E). Also, we found TPX2 expression had a negative relationship with 3-year DFS of esophageal squamous cell cancer ($n = 2$, $\text{OR} = 3.72, 95\% \text{ CI: } 1.34–12.73, P = .01$) (Fig. 4A) and hepatocellular cancer ($n = 2$, $\text{OR} = 4.09, 95\% \text{ CI: } 1.06–15.80, P = .04$) (Fig. 5B), and with 5-year DFS of hepatocellular cancer ($n = 2$, $\text{OR} = 4.13, 95\% \text{ CI: } 1.34–12.73, P = .01$) (Fig. 5D). However, significant relationship between TPX2 expression and 5-year OS/DFS of esophageal squamous cell carcinoma was not found (both $P = .05$) (Figs. 4D and 5C).

### 3.4. Sensitivity analyses

Removing the researches with NOS score < 7 did not affect results for OS at 3 or 5 years ($\text{OR} = 4.93, 95\% \text{ CI: } 3.35–7.24, P < .00001; \text{OR} = 4.63, 95\% \text{ CI: } 3.19–6.74, P < .00001$, respectively), and did not affect results for DFS at 3 or 5 years ($\text{OR} = 3.88, 95\% \text{ CI: } 1.83–8.15, P = .0003; \text{OR} = 3.16, 95\% \text{ CI: } 1.65–6.05, P = .0005$, respectively) as well. Elimination of these studies did not reduce heterogeneity for 3-year OS, 3-year DFS, or 5-year DFS (Cochran $Q = .14, I^2 = 34\%$; Cochran $Q = .08, I^2 = 56\%$; Cochran $Q = .15, I^2 = 43\%$, respectively), but reduce heterogeneity for 5-year OS (Cochran $Q = .23, I^2 = 24\%$).

Removing the studies that TPX2 expression was not detected by IHC did not affect results for OS at 3 or 5 years ($\text{OR} = 4.91, 95\% \text{ CI: } 3.43–7.04, P < .00001; \text{OR} = 4.90, 95\% \text{ CI: } 3.41–7.04, P < .00001$, respectively), and did not affect results for DFS at 3 or 5 years ($\text{OR} = 2.99, 95\% \text{ CI: } 1.63–5.49, P = .0004$) as well. Exclusion of these studies did not reduce heterogeneity for 3-year OS, 3-year

| Study or Subgroup | TPX2+ Events | TPX2+ Events Total | Odds Ratio M–H, Random, 95% CI |
|-------------------|--------------|-------------------|-------------------------------|
| Esophageal squamous cell cancer | 12 | 18 | 2.14 (0.99, 4.56) |
| Hepatocellular cancer | 38 | 40 | 2.40 (1.04, 5.54) |
| Esophageal squamous cell cancer | 12 | 14 | 2.40 (1.04, 5.54) |
| Hepatocellular cancer | 38 | 40 | 2.40 (1.04, 5.54) |

Figure 5. Subgroup analysis of disease-free survival (DFS) at 3 and 5 years by the expression level of TPX2 in different cancer types. A, Esophageal squamous cell cancer and 3-year overall survival (OS). B, Hepatocellular cancer and 3-year OS. C, Esophageal squamous cell cancer and 5-year OS. D, Hepatocellular cancer and 5-year OS. CI = confidence interval, TPX2 = targeting protein for Xklp2.
3.5. Publication bias

Funnel plot analysis was performed to estimate the potential bias in the included publications, and results revealed that there was no significant publication bias for OS and DFS in our meta-analysis (Fig. 6).

4. Discussion

The initiation and progression of tumors is a complex process with many factors may make a contribution, among them is the dysfunction of MT.[34] TPX2 is a kind of MAP controls MT function and dynamics, and therefore may play an important role in the development of tumors.

Recently, a systematic review containing 10 studies with 906 patients was carried out by Gang et al. Results showed that TPX2 was overexpression in most digestive system tumors and their expression status was associated with obviously worse survival rate.[35] In addition to digestive system tumors, TPX2 overexpression also exists in many other kinds of malignant neoplasms. Most studies suggest that enhanced expression of TPX2 in tumor tissue worsens the clinical outcome and decreasing TPX2 levels may be a beneficial approach for cancer treatment. For instance, Yan et al found that transfection of TPX2 siRNA decreased the viability and proliferation capacity of bladder carcinoma cell lines and TPX2-depleted tumor cells obviously grew more slowly in nude mice.[25] However, Pan et al suggested that the TPX2 expression level was not significantly different in relation to cumulative survival in human prostate cancer patients.[30] In light of the significant role of TPX2 in clinical application, we performed this meta-analysis to evaluate the relationship between TPX2 expression and prognosis of patients with various solid tumors.

In this systematic analysis, we pooled and evaluated survival data from 13 studies, which including 2134 patients, and demonstrated that the elevated expression of TPX2 was a prognostic marker of unfavorable clinical outcome, with consistent results of OS or DFS at 3 and 5 years. In the subgroup analysis stratified by tumor types, elevated TPX2 expression was associated with unfavorable 3- and 5-year OS/DFS of hepatocellular cancer and gastric cancer. And though overexpression of TPX2 was related to worse 3-year OS/DFS of esophageal squamous cell cancer, no significant relationship between TPX2 expression and 5-year OS/DFS of esophageal squamous cell cancer.

Figure 6. A, Publication bias funnel plot of the studies assessing targeting protein for Xklp2 (TPX2) expression and 3-year overall survival in solid tumors. B, Publication bias funnel plot of the studies assessing TPX2 expression and 5-year overall survival in solid tumors. C, Publication bias funnel plot of the studies assessing TPX2 expression and 3-year disease-free survival in solid tumors. D, Publication bias funnel plot of the studies assessing TPX2 expression and 5-year disease-free survival in solid tumors. Visual inspection of the funnel plot did not identify substantial asymmetry.
cancer was found. Moreover, 1 study showed that TPX2 overexpression in prostate cancer tissues was associated with preferable 5-year OS. As far as we know, TPX2 is a protein with several functional regions. Its N-terminus directly binds to and activated Aurora A kinase, which is a potential cancer marker for cell proliferation.[16] And its C-terminus binds to Eg5 and Xbplp2 kinesin (named "targeting protein for Xklp2" for that reason), mediating these motors’ spindle localization.[3,37] Except for these, unfortunately, we know little about the molecular mechanism and function of TPX2 in cancer pathogenesis, and cannot explain why TPX2 plays a catalytic role in some tumors, but not in others. These discrepancies suggest further attention should be paid to discover how TPX2 works at the cellular and molecular levels.

What is novel about this research is that it is the first systematic evaluation of the literatures with respect to TPX2 expression and clinical outcomes in patients with various solid tumors. This research also involves several meaningful implications. Firstly, it shows that in most solid tumors, TPX2 overexpression is correlated with unfavorable outcomes. Thus, along with imaging technology and other tumor biomarkers,[14–40] TPX2 may play an essential role in assessing the prognosis of various neoplasms. Secondly, by subgroup analysis, TPX2 expression presents negative relation with outcomes in gastric cancer and hepatocellular cancer, but irrelevant to long-term outcome in esophageal squamous cell cancer, which indicated that the function of TPX2 may be heterogeneous in different tumors.

There are also several limitations presented in our meta-analysis. First, some survival data were extracted from Kaplan-Meier curves artifically; thus, slight deviations may exist, although they could hardly influence the analysis results. Second, the detection methods and cut-off values of TPX2 expression are nonuniform in different articles. Third, stratification analysis for most types of tumor failed to be performed, because there were not enough date so far. Lastly, most researches included in our meta-analysis were performed in China. Thus, no firm conclusions can be drawn in other kinds of people and the differences between human races are uncertain. Further studies need to be performed to confirm the impact of human species on the results of studies.

In conclusion, our meta-analysis demonstrates that TPX2 overexpression is related to unfavorable outcome in most solid tumors, implying that TPX2 is a potential prognostic marker and therapeutic target for various solid tumors.

Acknowledgments

The authors thank the members of the laboratory for their helpful comments.

Author contributions

Data curation: Shijie Wang, Yongyuan Chen.
Project administration: Ying Chai.
Writing – original draft: Shijie Wang.
Writing – review and editing: Yongyuan Chen, Ying Chai.
Ying chai orcid: 0000-0002-4179-050X.

References

[1] Heidebrecht HJ, Buck F, Steinmann J, et al. Parwaresch R, p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. Blood 1997;90:226-33.

[2] Wittmann T, Boleti H, Antony C, et al. Localization of the kinesin-like protein Xklp2 to spindle poles requires a leucine zipper, a microtubule-associated protein, and dynein. J Cell Biol 1998;143:673-83.

[3] Wittmann T, Wilm M, Karsenti E, et al. TPX2, A novel xenopus MAP involved in spindle pole organization. J Cell Biol 2000;149:1405-18.

[4] Aguirre-Portoles C, Bird AW, Hyman A, et al. TPX2 controls spindle integrity, genome stability, and tumor development. Cancer Res 2012; 72:1518-28.

[5] Neumayer G, Beliz G, Gruss OJ, et al. TPX2: of spindle assembly, DNA damage response, and cancer. Cell Mol Life Sci 2014;71:3027-47.

[6] Perez de Castro I, Malumbres M. Mitotic stress and chromosomal instability in cancer: the case for TPX2. Genes Cancer 2012;3:721-30.

[7] Joukov V, De Nicolio A. Aurora-PLK1 cascades as key signaling modules in the regulation of mitosis. Sci Signal 2018;11(546):eaat1915.

[8] Ma S, Rong X, Gao F, et al. TPX2 promotes cell proliferation and migration via PLK1 in OC. Cancer Biomark 2018;22:443–51.

[9] Van Gijn SE, Wierenga E, Van den Tempel N, et al. TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells. Oncogene 2018;37:3611–19.

[10] Huang D, Chen J, Yang C, et al. TPX2 silencing mediated by joint action of microvesicles and ultrasonic radiation inhibits the migration and invasion of SKOV3 cells. Mol Med Rep 2018;17:7627–35.

[11] Kadara H, Lacroix L, Behrens C, et al. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) 2009;2:702–11.

[12] Liu Q, Tu K, Zhang H, et al. TPX2 as a novel prognostic biomarker for hepatocellular carcinoma. Hepatol Res 2013;45:906–18.

[13] Takahashi Y, Sheridan P, Nuida A, et al. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC. Ann Oncol 2015;26:935–42.

[14] Warner SL, Stephens BJ, Nwokenkwo S, et al. Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res 2009;15:6519–28.

[15] Shigeshi H, Ohra K, Hiraoka M, et al. Expression of TPX2 in salivary gland carcinomas. Oncol Rep 2009;21:341–4.

[16] Moshenifar J, Almassi-Aghdam M, Mohammad-Taberi Z, et al. Prognostic values of proliferative markers ki-67 and reap56 in breast cancer. Arch Iran Med 2007;10:27–31.

[17] Chang H, Wang J, Tian Y, et al. The TPX2 gene is a promising diagnostic and therapeutic target for cervical cancer. Oncol Rep 2012; 27:1553–9.

[18] Jiang P, Shen K, Wang X, et al. TPX2 regulates tumor growth in human cervical carcinoma cells. Mol Med Rep 2014;9:2347–51.

[19] Li B, Qi XQ, Chen X, et al. Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. Brain Res 2010;1352:200–7.

[20] Caceres-Gorrini KY, Carmona E, Barres V, et al. RAN nucleocytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian carcinoma. PLoS One 2014;9:e91900.

[21] Chen QL, Cao B, Nan N, et al. TPX2 in human clear cell renal carcinoma: expression, function and prognostic significance. Oncol Lett 2016; 11:3513–18.

[22] Tomi C, Inokuchi M, Takagi Y, et al. TPX2 expression is associated with poor survival in gastric cancer. World J Surg Oncol 2017;15:14.

[23] Shao C, Duan C, Wang J, et al. Expression of microtubule-associated protein TPX2 in human gastric carcinoma and its prognostic significance. Cancer Cell Int 2016;16:79.

[24] Liang B, Zheng W, Fang L, et al. Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer. Cancer Biol Ther 2016;17:824–32.

[25] Yan L, Li S, Xu C, et al. Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma. Tumour Biol 2013;34:4089–100.

[26] Hsu PK, Chen HY, Yeh YC, et al. TPX2 expression is associated with cell proliferation and patient outcome in esophageal squamous cell carcinoma. J Gastroenterol 2014;49:1231–40.

[27] Huang Y, Guo W, Kan H. TPX2 is a prognostic marker and contributes to growth and metastasis of human hepatocellular carcinoma. Int J Mol Sci 2014;15:18148–61.

[28] Wei P, Zhang N, Xu Y, et al. TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer. J Transl Med 2013;11:333–1313.

[29] Ma Y, Lin D, Sun W, et al. Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Clin Cancer Res 2006; 12:1121–7.
[30] Pan H-W, Su H-H, Hsu C-W, et al. Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer. Onco Targets Ther 2017;10:3531–43.

[31] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.

[32] Wells G, Shea B, O’Connell J. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014; The Ottawa Hospital Research Institute.

[33] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.

[34] Stumpff J, Ghule PN, Shimamura A, et al. Spindle microtubule dysfunction and cancer predisposition. J Cell Physiol 2014;229:1881–3.

[35] Wang G, Wang Q, Li Z, et al. Clinical value of Xenopus kinesin-like protein 2 as a prognostic marker in patients with digestive system cancers: a systematic review and meta-analysis. Onco Targets Ther 2018;11:1229–43.

[36] Zorba A, Buosi V, Kutter S, et al. Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2. Elife 2014;3:e02667.

[37] Ma N, Tulu US, Ferenz NP, et al. Poleward transport of TPX2 in the mammalian mitotic spindle requires dynein, Eg5, and microtubule flux. Mol Biol Cell 2010;21:979–88.

[38] Razek AA, Fathy A, Gawad TA. Correlation of apparent diffusion coefficient value with prognostic parameters of lung cancer. J Comput Assist Tomogr 2011;35:248–52.

[39] Razek AA, Gaballa G, Denewer A, et al. Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors. NMR Biomed 2010;23:619–23.

[40] Surov A, Nagata S, Razek AA, et al. Comparison of ADC values in different malignancies of the skeletal musculature: a multicentric analysis. Skeletal Radiol 2015;44:995–1000.